BEDFORD, Mass., Nov. 19, 2014 /PRNewswire/ -- Hologic, Inc.
(NASDAQ: HOLX), today announced the launch of the next-generation
NovaSure 6mm global endometrial ablation (GEA) system. The NovaSure
system is designed to apply radiofrequency energy to the
endometrium and gently remove the lining of the uterus in two
minutes or less. The new system offers customers a smaller diameter
(6mm) ablation device and an advanced interactive touchscreen
radiofrequency controller. The Company expects a full market
release in both the domestic and international markets for the new
NovaSure 6mm device in December
2014.
The NovaSure product enhancements are designed to improve
patient comfort and physician ease-of-use while maintaining the
clinical efficacy of the system. The new 6mm device requires less
dilation and is designed to improve patient comfort - especially
for patients under local anesthesia and/or paracervical block
in-office. An advanced radiofrequency touchscreen controller
provides physicians with procedural instructions on the controller
interface along with an ablation timer and procedural summary
screen.
The NovaSure system is used to treat women with abnormal uterine
bleeding or heavy periods, a condition that affects one in five
women 35-49 years old. NovaSure endometrial ablation is a one-time,
five-minute procedure that can be done in the doctor's office. To
date over 2 million women have chosen the NovaSure procedure to
treat the problem of lifestyle-restricting menstrual
periods.
"Our next-generation NovaSure system provides feature
enhancements that our customers have been requesting while
maintaining the efficacy of the NovaSure ablation profile that has
proven superior to other endometrial ablation modalities for over
10 years," said Carter Houghton,
Hologic's Senior Vice President and General Manager, GYN Surgical
Solutions. "NovaSure is the global market leader in endometrial
ablation because it offers women a safe, effective and quick
solution to excessive menstrual bleeding. The NovaSure procedure
does not involve major surgery and allows women to return to their
normal routines quickly, usually the next day. Additionally, the
NovaSure procedure can result in health care savings, an
important consideration in today's economic environment."
About the NovaSure System:
The NovaSure endometrial ablation system is a minimally invasive
treatment for abnormal uterine bleeding (AUB). The system is
designed to apply radiofrequency energy to the endometrium and
gently remove the lining of the uterus in two minutes or less. The
procedure requires no incisions, can be performed at any time
during the menstrual cycle, and is often performed in an
outpatient/office setting, providing flexibility to both the
patient and physician. The NovaSure procedure typically allows
patients to return to their normal activities the next day.
Unlike other endometrial ablation treatments, the NovaSure
procedure is customized to each patient with a scientific endpoint
and requires no hormonal pre-treatment, which is often associated
with side-effects and treatment delays.
The NovaSure procedure provides a safe and effective alternative
to hysterectomy or to less effective medical therapy for women
suffering from excessive menstrual bleeding. With over 2 million
procedures now performed, the NovaSure procedure is one of the most
trusted and proven endometrial ablation modalities on the market.
For more information, please visit www.novasure.com.
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal health. With
a unified suite of technologies and a robust research and
development program, Hologic is dedicated to The Science of Sure.
For more information on Hologic, visit www.hologic.com.
Hologic, NovaSure and associated logos are trademarks and/or
registered trademarks of Hologic, Inc., and/or its subsidiaries in
the United States and/or other
countries.
Forward-looking Statement Disclaimer:
This News Release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic's NovaSure system. There can be no assurance the
product will achieve the benefits described herein and that such
benefits will be replicated in any particular manner with respect
to an individual patient as the actual effect of the use of the
product can only be determined on a case-by-case basis depending on
the particular circumstances and patient in question. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such statements
are based.
|
Contacts:
|
|
|
Marianne
McMorrow
|
Jim Culley
|
Manager, Corporate
Communications
|
Senior Director,
Corporate Communications
|
(781)
999-7723
|
(302)
528-1312
|
marianne.mcmorrow@hologic.com
|
jim.culley@hologic.com
|
SOURCE Hologic, Inc.